Clinical Trial Detail

NCT ID NCT03421353
Title AZD9150 Plus Durvalumab Alone or in Combination With Chemotherapy in Patients With Advanced, Solid Tumours and in Patients With Non-Small-Cell Lung Cancer
Recruitment Recruiting
Gender both
Phase Phase Ib/II
Variant Requirements yes
Sponsors AstraZeneca
Indications

Advanced Solid Tumor

non-small cell lung carcinoma

Therapies

AZD9150 + Cisplatin + Durvalumab + Gemcitabine

AZD9150 + Carboplatin + Durvalumab + Gemcitabine

AZD9150 + Cisplatin + Durvalumab + Fluorouracil

AZD9150 + Durvalumab

AZD9150 + Carboplatin + Durvalumab + Nab-paclitaxel

Age Groups: adult senior

Additional content available in CKB BOOST